{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DL4&page=3", "query": { "intervention": "DL4", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 51, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DL4&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DL4&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T18:25:21.156Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03547700", "title": "Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, T-Cell, Peripheral" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2018-09-26", "completion_date": "2020-08-27", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 7, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03547700" }, { "nct_id": "NCT06879041", "title": "A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "AZD2287", "type": "DRUG" }, { "name": "AZD2275", "type": "DRUG" }, { "name": "AZD2284", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 136, "start_date": "2025-03-10", "completion_date": "2029-04-16", "has_results": false, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 12, "location_summary": "Palo Alto, California • San Diego, California • Miami, Florida + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06879041" }, { "nct_id": "NCT05769920", "title": "Dose Escalation TTHX1114 Ophthalmic Solution", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Corneal Epithelial Degeneration" ], "interventions": [ { "name": "TTHX1114(NM141) Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trefoil Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2022-12-06", "completion_date": "2023-04-12", "has_results": false, "last_update_posted_date": "2023-04-18", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05769920" }, { "nct_id": "NCT02073097", "title": "Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Vincristine sulfate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Acyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2015-01-28", "completion_date": "2023-06-29", "has_results": true, "last_update_posted_date": "2024-05-29", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 3, "location_summary": "Buffalo, New York • Cleveland, Ohio", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073097" }, { "nct_id": "NCT00738751", "title": "Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Head and Neck Cancer" ], "interventions": [ { "name": "Panobinostat (LBH589)", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2008-11", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-02-04", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738751" }, { "nct_id": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1438, "start_date": "2025-08-12", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 19, "location_summary": "Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070232" }, { "nct_id": "NCT05064358", "title": "Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Belantamab mafodotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 177, "start_date": "2022-03-03", "completion_date": "2026-02-10", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 6, "location_summary": "West Palm Beach, Florida • Kansas City, Missouri • New York, New York + 3 more", "locations": [ { "city": "West Palm Beach", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chattanooga", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064358" }, { "nct_id": "NCT07815561", "title": "Phase 1 Study Involving SAB01 and Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Participants" ], "interventions": [ { "name": "Subcutaneous (SC) single dose of SAB01", "type": "DRUG" }, { "name": "Intravenous (IV) infusion of SAB01", "type": "DRUG" }, { "name": "Placebo SC", "type": "DRUG" }, { "name": "Placebo IV Infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santa Ana Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 88, "start_date": "2026-08-31", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07815561" }, { "nct_id": "NCT02443402", "title": "Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Regular Human Insulin", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Supplemental insulin (Insulin lispro)", "type": "DRUG" }, { "name": "Supplemental insulin (Insulin aspart)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 68, "start_date": "2016-01", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-06", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 4, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02443402" }, { "nct_id": "NCT01676753", "title": "Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Breast Cancer", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Dinaciclib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jo Chien", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 32, "start_date": "2016-12-28", "completion_date": "2022-02-28", "has_results": false, "last_update_posted_date": "2022-09-21", "last_synced_at": "2026-10-10T18:25:21.156Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01676753" } ] }